Reuters logo
Merck KGaA says Phase III trial of Cilengitide fails
February 25, 2013 / 6:51 AM / 5 years ago

Merck KGaA says Phase III trial of Cilengitide fails

FRANKFURT, Feb 25 (Reuters) - Germany’s Merck KGaA said a Phase III trial of Cilengitide - a therapy against an aggressive type of brain tumour - did not meet its primary endpoint of significantly increasing overall survival when added to chemoradiotherapy. (Reporting by Marilyn Gerlach)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below